The tweet was deleted by the author.
But we saved everything 🙂.
Bicara Therapeutics Inc. announced its financial results for the second quarter of 2026, highlighting notable changes in company leadership and a strategic shift to accelerate its operational growth.
The company also reported continued advancement in its pivotal Phase 2/3 FORTIFI-HN01 clinical trial and outlined recent achievements along with key milestones anticipated in the near term. These developments signal a new phase for Bicara Therapeutics Inc. as it focuses on expanding its clinical efforts and advancing its therapeutic pipeline.
View post on X Loading...
Ahead of the latest earnings announcement, Bicara Therapeutics had scheduled the release of its Q2 2026 financial results and a business update conference call for August 11, as detailed in a previous company notice. The company recently appointed Jeremy Bender and Christy Oliger, both with significant biopharma expertise, to its board of directors in a recent board update. These steps reflect ongoing changes in Bicara's governance and communication with stakeholders.